Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Five new directors at Novelos

This article was originally published in Scrip

Executive Summary

Novelos Therapeutics, a US-based pharmaceutical company developing drugs for the treatment and diagnosis of cancer, has announced that Dr Rock Mackie, John Neis, Dr John Niederhuber, Dr Michael Tweedle and Dr Jamey Weichert have been appointed to its board of directors, concurrent with the closing of the recently announced acquisition of Cellectar. Dr Mackie, professor of medical physics and human oncology at the University of Wisconsin, is co-founder, chairman and director of research of TomoTherapy; Mr Neis heads the healthcare practice at Venture Investors; Dr Niederhuber was a professor and director of National Cancer Institute from 2005-10, national cancer advisory board chair, grant reviewer and investigator; Dr Tweedle, professor of cancer imaging in radiology at Ohio State, is the former president of Bracco Research USA and head of diagnostics at Bristol-Myers Squibb; and Dr Weichert, Novelos’ chief scientific officer and technology founder, is an associate professor of radiology and medical physics at University of Wisconsin.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts